{
  "id": "al-amyloidosis",
  "title": "AL Amyloidosis",
  "lang": "en",
  "source_lang": "en",
  "summary": "AL amyloidosis is a disorder in which misfolded immunoglobulin light chains form tissue deposits that can damage the heart, kidneys, nerves, and other organs.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Immunoglobulin light-chain amyloidosis",
    "Light-chain amyloidosis",
    "Primary amyloidosis",
    "Primary systemic amyloidosis"
  ],
  "generated_at": "2026-11-06",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/al-amyloidosis/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/al-amyloidosis/",
      "json": "https://aiwiki.page/zh/al-amyloidosis.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "AL amyloidosis is a form of amyloidosis caused by misfolded immunoglobulin light chains, proteins normally produced as components of antibodies. These light chains are usually made by an abnormal population of plasma cells in the bone marrow. They aggregate into insoluble amyloid fibrils that accumulate outside cells and impair tissue function. Systemic AL amyloidosis can affect several organs, especially the heart and kidneys, and may be life-threatening even when the underlying plasma-cell population is small. The letters AL identify the amyloid protein as an immunoglobulin light chain."
    },
    {
      "heading": "Biological basis",
      "text": "Antibodies contain heavy chains and light chains. Light chains occur in two types, kappa and lambda. In AL amyloidosis, a clone of antibody-producing cells releases light chains whose molecular properties make them susceptible to misfolding and aggregation. Lambda light chains are more commonly involved than kappa light chains.\n\nAmyloid fibrils have an ordered, cross-beta-sheet structure. Their accumulation disrupts tissue architecture, while soluble abnormal light chains and intermediate aggregates can also exert direct cellular toxicity. Organ damage therefore reflects more than the physical quantity of deposited material.\n\nThe responsible cell population is usually a plasma-cell clone, although some cases arise from other antibody-producing B-cell disorders. AL amyloidosis may coexist with multiple myeloma, but the two diagnoses are not equivalent: many people with AL amyloidosis do not meet criteria for myeloma. Conversely, detecting a monoclonal protein does not establish amyloidosis.\n\nSystemic AL amyloidosis is generally an acquired disorder rather than an inherited amyloid disease. Localized light-chain amyloid deposits can also occur, for example in the respiratory tract, urinary bladder, or skin. These often reflect local light-chain production and differ from systemic AL amyloidosis in evaluation and clinical course."
    },
    {
      "heading": "Clinical manifestations",
      "text": "Presentation depends on the organs involved. Early symptoms, including fatigue, weight loss, swelling, and reduced exercise tolerance, are nonspecific.\n\nHeart\n\nCardiac involvement can cause thickening and stiffness of the ventricular walls, impaired filling, and heart failure. Breathlessness, fluid retention, low blood pressure, rhythm disturbances, and conduction abnormalities may occur. A normal or relatively preserved left ventricular ejection fraction does not exclude severe cardiac disease.\n\nOn cardiac imaging, increased wall thickness may contrast with relatively low electrical voltage on electrocardiography, although this combination is not present in every case. Cardiac involvement is a major determinant of survival.\n\nKidneys\n\nAmyloid deposits in the kidneys commonly cause protein loss in urine. Heavy protein loss may produce nephrotic syndrome, characterized by marked proteinuria, low blood albumin, and edema. Progressive loss of filtration can lead to chronic kidney disease. Substantial proteinuria may occur before filtration becomes severely impaired.\n\nNerves and other tissues\n\nPeripheral nerve involvement can produce numbness, burning pain, and sensory loss. Autonomic nerve dysfunction may cause a fall in blood pressure on standing, abnormal sweating, erectile dysfunction, and disturbances of bowel function.\n\nOther manifestations include liver enlargement, gastrointestinal symptoms, easy bruising, and soft-tissue infiltration. An enlarged tongue and purplish bruising around the eyes are characteristic clues but occur in only a minority of cases. Bleeding can result from vascular fragility or, less commonly, an acquired deficiency of clotting factor X."
    },
    {
      "heading": "Diagnosis",
      "text": "Diagnosis requires evidence of amyloid deposition, identification of the deposited protein, and assessment of the underlying clone and affected organs. Symptoms or a monoclonal blood protein alone are insufficient.\n\nDetecting the abnormal light chain\n\nThe usual laboratory evaluation combines:\n\n- Serum immunofixation.\n- Urine immunofixation.\n- Measurement of serum free light chains and the kappa-to-lambda ratio.\n\nThese tests are complementary. Routine serum protein electrophoresis alone may miss the small monoclonal protein associated with AL amyloidosis. Kidney dysfunction can alter free-light-chain concentrations and ratios, complicating interpretation.\n\nBone marrow examination characterizes the plasma-cell or other B-cell clone. It may include morphology, flow cytometry, and genetic testing.\n\nDemonstrating and typing amyloid\n\nA tissue biopsy can demonstrate amyloid with Congo red staining, classically showing apple-green birefringence under polarized light. Abdominal fat sampling and bone marrow biopsy are commonly used relatively low-risk sampling approaches, but negative results do not exclude the disease. Biopsy of an affected organ may be necessary when other samples are nondiagnostic.\n\nThe deposited protein must be identified. Laser microdissection followed by mass spectrometry is an important method for amyloid typing; validated immunohistochemical or immunoelectron-microscopic methods are also used in specialist laboratories.\n\nAccurate typing is essential because monoclonal gammopathy of undetermined significance can coexist with an unrelated amyloid disorder, particularly transthyretin amyloidosis. Finding a monoclonal protein must not automatically lead to classification as AL.\n\nAssessing organ involvement\n\nEvaluation commonly includes urine protein measurements, kidney and liver function tests, cardiac biomarkers, echocardiography, and sometimes cardiac magnetic resonance imaging. Troponin and natriuretic peptides, including NT-proBNP, help assess cardiac injury and stress.\n\nBone-tracer scintigraphy has an important role in diagnosing transthyretin cardiac amyloidosis under defined conditions, but it does not independently establish or reliably exclude AL amyloidosis."
    },
    {
      "heading": "Treatment",
      "text": "Treatment of systemic AL amyloidosis targets the abnormal cell clone to reduce production of harmful light chains. It also addresses the consequences of organ dysfunction. Selection and intensity depend strongly on cardiac status, other organ involvement, and overall fitness.\n\nA widely used initial regimen combines daratumumab, a CD38-directed monoclonal antibody, with bortezomib, cyclophosphamide, and dexamethasone. The randomized ANDROMEDA trial established improved hematologic responses with the addition of daratumumab to this combination. Patients with the most advanced cardiac disease were excluded from that trial, limiting direct application of its findings to that group.\n\nSelected patients receive high-dose melphalan followed by autologous hematopoietic stem-cell transplantation. Eligibility is restricted because severe cardiac or other organ involvement can make the procedure hazardous. Relapsed or refractory disease may be treated with other plasma-cell-directed regimens according to prior exposure, response, and tolerability.\n\nSupportive care addresses fluid overload, kidney failure, autonomic dysfunction, nutritional problems, and other complications. Advanced organ disease can limit tolerance of both anticlonal treatment and medications routinely used for other causes of heart failure. Dialysis and, in carefully selected circumstances, organ transplantation may form part of management."
    },
    {
      "heading": "Response assessment and prognosis",
      "text": "Treatment response is assessed at two distinct levels:\n\n- Hematologic response: reduction or disappearance of the abnormal light-chain signal and monoclonal protein.\n- Organ response: improvement in measures such as cardiac biomarkers or urinary protein loss.\n\nA deep hematologic response can occur before measurable organ improvement. Previously deposited amyloid and established tissue damage may persist after light-chain production has been suppressed.\n\nPrognosis varies substantially. Cardiac involvement, particularly advanced cardiac dysfunction, is the strongest adverse factor. Established staging systems use cardiac biomarkers; some also incorporate the difference between involved and uninvolved serum free-light-chain concentrations. Kidney function and proteinuria provide additional information about the risk of progression to dialysis.\n\nOutcomes have improved with more effective plasma-cell-directed treatment, but advanced cardiac AL amyloidosis retains a high risk of early death. Survival estimates depend on disease stage, treatment era, and the population studied, making a single overall survival figure misleading."
    }
  ],
  "links": [
    "antibody",
    "plasma-cell",
    "bone-marrow",
    "multiple-myeloma",
    "kidney",
    "chronic-kidney-disease",
    "diagnosis",
    "biopsy",
    "mass-spectrometry",
    "monoclonal-gammopathy-of-undetermined-significance",
    "magnetic-resonance-imaging",
    "monoclonal-antibody",
    "hematopoietic-stem-cell-transplantation",
    "prognosis"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}